Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Izokibep in Moderate to Severe Hidradenitis Suppurativa
2022-503160-33-00Phase 3Completed
- Sponsor
- Acelyrin
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Izokibep with Placebo (2 arms). Primary endpoint: HiSCR75 at Week 12. Started Nov 2023; status: completed.
02
Drugs
izokibep
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2022-503160-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503160-33-00.